A 52-year-old woman with HER2-positive metastatic breast cancer is being considered for trastuzumab versus lapatinib. Which clinical feature would best favor the use of lapatinib over trastuzumab?

Explanation

## Trastuzumab vs Lapatinib: Clinical Discriminators **Key Point:** The choice between trastuzumab (monoclonal antibody) and lapatinib (TKI) depends on tumor location, cardiac tolerance, and mechanism-of-action requirements. ### Comparative Profile | Feature | Trastuzumab | Lapatinib | |---------|-------------|----------| | **Drug class** | Monoclonal antibody (IgG1) | Tyrosine kinase inhibitor (small molecule) | | **Targets** | HER2 extracellular domain | HER2 and EGFR intracellular kinase domains | | **BBB penetration** | Poor (large protein) | Excellent (small, lipophilic) | | **CNS metastases** | Ineffective | Effective | | **Cardiotoxicity** | Moderate–high (HER2 in cardiomyocytes) | Lower (less cardiac HER2 inhibition) | | **ADCC/CDC** | Yes (key mechanism) | No | | **Mechanism in resistant disease** | Overcomes some resistance via ADCC | Overcomes by dual EGFR/HER2 inhibition | ### Why Lapatinib for Brain Metastases **High-Yield:** Lapatinib, being a small-molecule TKI, penetrates the blood-brain barrier and achieves therapeutic concentrations in CNS tissue. Trastuzumab, a large hydrophilic antibody, does not cross an intact BBB and is therefore ineffective for brain metastases. This is the **cardinal clinical discriminator** for lapatinib selection. **Clinical Pearl:** A patient with HER2-positive breast cancer and brain metastases should receive lapatinib (or other CNS-penetrant agents like tucatinib) rather than trastuzumab, as the latter will not reach effective concentrations in the CNS. ### Cardiac Safety Consideration **Warning:** Trastuzumab carries a significant risk of cardiotoxicity (dilated cardiomyopathy, HF) because HER2 is expressed in cardiomyocytes and is essential for cardiac homeostasis. Lapatinib, while also inhibiting HER2, causes less cardiac dysfunction because it does not fully inhibit the cardioprotective HER2 signaling in the same manner. In a patient with borderline ejection fraction (45%) and prior anthracycline exposure, lapatinib would be safer. **Mnemonic:** **BBB-TKI = Blood-Brain-Barrier penetration by Tyrosine Kinase Inhibitors** — remember that small molecules cross BBB, large antibodies do not.